Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease

NCT05094011 is registered in ClinicalTrials.gov with Taiwan Mitochondrion Applied Technology Co., Ltd. as lead sponsor.

NCT NCT05094011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05094011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease
Lead sponsor
Taiwan Mitochondrion Applied Technology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
July 31, 2028
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease